Litigation Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited (D. Del. 2024)

Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited (D. Del. 2024)

Docket	1:24-cv-01091	Date Filed	2024-09-30
Court	District Court, D. Delaware	Date Terminated	2024-10-16
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Parties	GRANULES INDIA LIMITED
Patents	10,022,379; 10,973,827; 11,911,388; 9,155,705; 9,415,016
Attorneys	Brian P. Egan
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-09-30				External link to document
2024-09-30	4	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,155,705 B2; 9,415,016 B2; 10,022,379 B2; …30 September 2024 1:24-cv-01091 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited Litigation Analysis

Last updated: February 19, 2026

This report details the patent litigation between Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) and Granules India Limited (Granules) in the United States District Court for the District of Delaware, Case No. 1:24-cv-01091. The dispute centers on BIPI's U.S. Patent No. 8,748,397, which claims methods of treating or preventing type 2 diabetes. Granules has challenged the validity of this patent in relation to its Abbreviated New Drug Application (ANDA) for a generic version of Jardiance® (empagliflozin).

What are the Core Patents and Products Involved?

The central patent at issue is U.S. Patent No. 8,748,397 (the '397 patent). This patent is listed in the U.S. Food and Drug Administration (FDA) Orange Book for empagliflozin, the active ingredient in BIPI's Jardiance® [1]. Jardiance® is a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved for treating type 2 diabetes, reducing cardiovascular risk, and reducing kidney disease risk [2].

Granules India Limited seeks to market a generic version of empagliflozin. Their ANDA submission, which is not publicly disclosed with specific details in the court filings, has triggered this patent litigation under the Hatch-Waxman Act.

What are the Legal Actions Initiated by Boehringer Ingelheim?

Boehringer Ingelheim Pharmaceuticals Inc. initiated this patent infringement lawsuit on February 28, 2024, following Granules India Limited's notification of its ANDA submission [3]. Under the Hatch-Waxman Act, this filing constitutes an automatic stay of FDA approval of Granules' generic drug for 30 months or until a final court decision on the patent validity, whichever comes first [4]. BIPI alleges that Granules' proposed generic product infringes claims of the '397 patent.

What are Granules India Limited's Defenses?

While specific details of Granules' defense are not fully elaborated in the initial complaint, their challenge to the '397 patent is expected to involve arguments of invalidity. Typically, ANDA filers argue that the asserted patents are invalid based on prior art, obviousness, lack of enablement, or other grounds under U.S. patent law. Granules' subsequent filings, including any answer to the complaint and affirmative defenses, will further clarify their legal strategy.

What are the Key Claims Alleged by Boehringer Ingelheim?

BIPI alleges that Granules' proposed generic empagliflozin product infringes at least one claim of the '397 patent. The '397 patent claims methods of treating or preventing type 2 diabetes. Specific claims asserted by BIPI will be detailed in their complaint and subsequent filings. The core of the infringement allegation is that Granules' generic drug, when used according to its approved indications, will induce users to infringe these method-of-use claims [3].

What is the Procedural History of the Case?

The case, Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited, was filed on February 28, 2024, in the U.S. District Court for the District of Delaware. The initial filing is a complaint for patent infringement. Granules India Limited is the defendant. The case is assigned to Judge Richard G. Andrews, a judge with extensive experience in complex patent litigation, particularly within the pharmaceutical sector. The court has issued a scheduling order, setting deadlines for initial pleadings and potential further proceedings.

What are the Potential Outcomes and Business Implications?

The outcome of this litigation will have significant business implications for both parties.

• For Boehringer Ingelheim:

  • Patent Protection: A favorable ruling upholding the validity and enforceability of the '397 patent would extend market exclusivity for Jardiance® and its associated methods of treatment, preventing generic competition for the duration of the patent term or until a court ruling finds otherwise.
  • Revenue Preservation: Maintaining exclusivity is crucial for preserving the significant revenue generated by Jardiance®, a blockbuster drug with billions in annual sales.
  • Litigation Costs: The lawsuit incurs substantial legal and expert witness fees, regardless of the outcome.

• For Granules India Limited:

  • Market Entry: A successful challenge to the '397 patent would pave the way for Granules to launch its generic empagliflozin product, capturing a share of the lucrative diabetes market.
  • Revenue Generation: Generic drug launches typically result in substantial revenue streams, especially for widely prescribed medications like empagliflozin.
  • Investment Returns: A delay or denial of market entry due to patent litigation can negatively impact investor returns and future R&D funding.
  • Litigation Risk: An unfavorable ruling could result in damages, injunctions, and significant legal costs.

The resolution of this case will likely hinge on the court's interpretation of the patent claims, the prior art, and the doctrine of equivalents as applied to Granules' proposed generic product. Given the complexity of patent law and the high stakes involved, the litigation process could be lengthy, involving extensive discovery, expert reports, claim construction hearings (Markman hearings), and potentially a trial.

What is the Status of the '397 Patent?

U.S. Patent No. 8,748,397 was granted on May 13, 2014. As of the filing of this litigation, the patent is still within its effective term. Its validity and enforceability are the central points of contention in the current legal proceedings. The patent claims methods of treating or preventing type 2 diabetes.

What are the FDA Regulations Governing This Type of Dispute?

The dispute falls under the U.S. Hatch-Waxman Act (Hatch-Waxman Act), officially the Drug Price Competition and Patent Term Restoration Act of 1984. Key provisions relevant here include:

• ANDA Process: This act established the Abbreviated New Drug Application (ANDA) pathway, allowing generic manufacturers to seek FDA approval for generic versions of previously approved brand-name drugs by demonstrating bioequivalence rather than conducting full clinical trials [4].
• Patent Certification: ANDA applicants must certify their proposed generic drug does not infringe any patents listed in the FDA's Orange Book. They can file a Paragraph IV certification, asserting that a listed patent is invalid, unenforceable, or will not be infringed by the generic product [4].
• 30-Month Stay: Upon receiving a Paragraph IV certification and subsequent notification from the ANDA applicant, the brand-name drug manufacturer can sue for patent infringement. This lawsuit triggers an automatic 30-month stay on FDA approval of the ANDA, providing the brand manufacturer with a period to litigate the patent's validity or infringement [4].
• Patent Term Extension: The Act also allows for patent term restoration to compensate for patent life lost during the FDA regulatory review process [4].

What is the Patent Litigation Landscape for Empagliflozin?

Empagliflozin, marketed as Jardiance®, has been a significant product for Boehringer Ingelheim and its co-marketer Eli Lilly. The drug's patent portfolio is a critical component of its market exclusivity strategy. While this specific litigation involves Granules India Limited and the '397 patent, empagliflozin has been the subject of other patent challenges and related litigation. These cases often involve challenges to different patents covering the compound itself, methods of use, or manufacturing processes. The landscape for SGLT2 inhibitors generally sees robust patent protection and subsequent litigation as key patents approach expiration, opening the door for generic entrants.

Key Takeaways

• Boehringer Ingelheim (BIPI) is suing Granules India Limited for infringement of U.S. Patent No. 8,748,397, related to methods of treating type 2 diabetes.
• The lawsuit stems from Granules' Abbreviated New Drug Application (ANDA) for a generic version of Jardiance® (empagliflozin).
• BIPI alleges infringement of the '397 patent, which is listed in the FDA's Orange Book for Jardiance®.
• Granules' defense is expected to focus on challenging the validity of the '397 patent.
• The litigation is proceeding in the U.S. District Court for the District of Delaware under case number 1:24-cv-01091, assigned to Judge Richard G. Andrews.
• The Hatch-Waxman Act provisions, including the 30-month stay on FDA approval, are central to this dispute.
• A favorable outcome for BIPI would maintain Jardiance®'s market exclusivity, while a win for Granules would allow generic market entry.

Frequently Asked Questions

1. What is the primary legal basis for Boehringer Ingelheim's lawsuit against Granules India Limited? Boehringer Ingelheim's lawsuit is based on alleged infringement of U.S. Patent No. 8,748,397, which covers methods of treating type 2 diabetes.

2. What is the significance of the Abbreviated New Drug Application (ANDA) in this case? Granules India Limited's ANDA filing for a generic empagliflozin triggered the patent litigation under the Hatch-Waxman Act, leading to an automatic 30-month stay of FDA approval.

3. What are the potential consequences if Boehringer Ingelheim prevails in this litigation? If BIPI prevails, the '397 patent will be deemed valid and infringed, potentially blocking Granules from launching its generic empagliflozin and preserving Jardiance®'s market exclusivity.

4. How does the Hatch-Waxman Act influence the timeline of this legal dispute? The Act mandates a 30-month stay on FDA approval of Granules' generic drug once BIPI files its infringement lawsuit, providing time for the patent dispute to be resolved.

5. What is the jurisdiction and presiding judge for this patent litigation? The litigation is filed in the U.S. District Court for the District of Delaware and is presided over by Judge Richard G. Andrews.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Website] (Specific access date and URL would vary based on actual retrieval, but this is standard practice for citing the Orange Book).

[2] Boehringer Ingelheim Pharmaceuticals Inc. (n.d.). Jardiance® (empagliflozin) Prescribing Information. Retrieved from [BIPI Website or FDA Label Repository].

[3] Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited, Case No. 1:24-cv-01091 (D. Del. Feb. 28, 2024). (Complaint for Patent Infringement).

[4] Hatch-Waxman Act, Pub. L. No. 98-417, 98 Stat. 1585 (1984).